Olaparib and adavosertib work best when given sequentially for DNA-damage response mutations in advanced tumors

by European Organisation for Research and Treatment of CancerCredit: Pixabay/CC0 Public DomainPatients with cancers that are driven by certain mutations occurring in response to DNA damage can be safe

Updated on: December 19,2023

Olaparib and adavosertib work best when given sequentially for DNA-damage response mutations in advanced tumors

by European Organisation for Research and Treatment of CancerCredit: Pixabay/CC0 Public DomainPatients with cancers that are driven by certain mutations occurring in response to DNA damage can be safe

Updated on:December 19,2023

Daratumumab Plus Induction Therapy Reduces Stem Cell Yield in Multiple Myeloma

June 9, 2023Tony Berberabe, MPHThe addition of daratumumab to frontline induction therapy prior to peripheral blood stem cell collection reduced the number of patients with newly diagnosed multiple my

Updated on: October 12,2023

Daratumumab Plus Induction Therapy Reduces Stem Cell Yield in Multiple Myeloma

June 9, 2023Tony Berberabe, MPHThe addition of daratumumab to frontline induction therapy prior to peripheral blood stem cell collection reduced the number of patients with newly diagnosed multiple my

Updated on:October 12,2023

Acute myeloid leukemia: Germany-wide clinical trial challenges international standard of care

by Nina Louis, Medizin & WissenschaftCredit:Blood(2022). DOI: 10.1182/blood-2022-159962Prior to allogeneic stem cell transplantation for the treatment of acute myeloid leukemia (AML),

Updated on: December 25,2023

Acute myeloid leukemia: Germany-wide clinical trial challenges international standard of care

by Nina Louis, Medizin & WissenschaftCredit:Blood(2022). DOI: 10.1182/blood-2022-159962Prior to allogeneic stem cell transplantation for the treatment of acute myeloid leukemia (AML),

Updated on:December 25,2023

Colorectal cancer risk remains despite modern treatment for ulcerative colitis

byKarolinska InstitutetJonas Ludvigsson, professor in the Department of Medical Epidemiology and Biostatistics at Karolinska Institutet in Sweden. Credit: Gustav MårtenssonPatients with the infl

Updated on: December 20,2023

Colorectal cancer risk remains despite modern treatment for ulcerative colitis

byKarolinska InstitutetJonas Ludvigsson, professor in the Department of Medical Epidemiology and Biostatistics at Karolinska Institutet in Sweden. Credit: Gustav MårtenssonPatients with the infl

Updated on:December 20,2023

Technology that determines success of CAR T-cell immunotherapy could advance treatment of lymphoma

by Laurie Fickman,University of HoustonNavin Varadarajan, M.D. Anderson Professor of chemical and biomolecular engineering, studied the dynamic interactions between T cells and tumor cells to de

Updated on: December 26,2023

Technology that determines success of CAR T-cell immunotherapy could advance treatment of lymphoma

by Laurie Fickman,University of HoustonNavin Varadarajan, M.D. Anderson Professor of chemical and biomolecular engineering, studied the dynamic interactions between T cells and tumor cells to de

Updated on:December 26,2023

Advancing gene therapy for skin cancer

by Federica Giannelli,University of SaskatchewanStudent Mays Al-Dulaymi improves gene therapy techniques. Credit: Dave StobbeOne of the deadliest skin cancers, melanoma may be caused by overexpo

Updated on: December 18,2023

Advancing gene therapy for skin cancer

by Federica Giannelli,University of SaskatchewanStudent Mays Al-Dulaymi improves gene therapy techniques. Credit: Dave StobbeOne of the deadliest skin cancers, melanoma may be caused by overexpo

Updated on:December 18,2023

Step forward in leukemia treatment

by South Australian Health and Medical Research InstituteCredit: AI-generated imageAn international clinical trial involving Adelaide researchers has demonstrated the safety and efficacy of a next-gen

Updated on: December 22,2023

Step forward in leukemia treatment

by South Australian Health and Medical Research InstituteCredit: AI-generated imageAn international clinical trial involving Adelaide researchers has demonstrated the safety and efficacy of a next-gen

Updated on:December 22,2023

Fixed-Duration Mosunetuzumab Elicits Durable Responses in R/R Follicular Lymphoma

June 27, 2023Kristi RosaFixed-duration treatment with single-agent mosunetuzumab resulted in a high complete response rate by end of treatment in patients with relapsed or refractory follicular lympho

Updated on: October 15,2023

Fixed-Duration Mosunetuzumab Elicits Durable Responses in R/R Follicular Lymphoma

June 27, 2023Kristi RosaFixed-duration treatment with single-agent mosunetuzumab resulted in a high complete response rate by end of treatment in patients with relapsed or refractory follicular lympho

Updated on:October 15,2023

Using the immune system to fight cancer: an interview with Dr Charles Akle

Why does cancer occur?We all produce as many as 100,000 different types of cancer cells every day, which are recognized and eliminated by our extraordinarily efficient immune system.However, if someth

Updated on: October 27,2023

Using the immune system to fight cancer: an interview with Dr Charles Akle

Why does cancer occur?We all produce as many as 100,000 different types of cancer cells every day, which are recognized and eliminated by our extraordinarily efficient immune system.However, if someth

Updated on:October 27,2023

A four-drug chemotherapy regimen improves survival in stage 4 pancreatic cancer: Phase 3 clinical trial

byUniversity of California, Los AngelesPancreatic cancer cells (blue) growing as a sphere encased in membranes (red). Credit: National Cancer InstituteA four-drug chemotherapy regimen provided l

Updated on: January 04,2024

A four-drug chemotherapy regimen improves survival in stage 4 pancreatic cancer: Phase 3 clinical trial

byUniversity of California, Los AngelesPancreatic cancer cells (blue) growing as a sphere encased in membranes (red). Credit: National Cancer InstituteA four-drug chemotherapy regimen provided l

Updated on:January 04,2024

What Comes after NCI-MATCH? NCI’s New Precision Medicine Cancer Trials

SubscribeDecember 6, 2023, by James H. Doroshow, M.D.Findings from NCI-MATCH and its successor trials will help oncologists implement precision medicine in everyday patient care.Credit: iStockMore tha

Updated on: December 19,2023

What Comes after NCI-MATCH? NCI’s New Precision Medicine Cancer Trials

SubscribeDecember 6, 2023, by James H. Doroshow, M.D.Findings from NCI-MATCH and its successor trials will help oncologists implement precision medicine in everyday patient care.Credit: iStockMore tha

Updated on:December 19,2023

Why men, wealthy people and maritime residents are more likely to develop skin cancer

byMcGill UniversityComparison of UV exposure and skin cancer history, sun protection and level of worry between high-incidence (PEI/NS) and low-incidence (NL) provinces for cutaneous melanoma.&n

Updated on: January 08,2024

Why men, wealthy people and maritime residents are more likely to develop skin cancer

byMcGill UniversityComparison of UV exposure and skin cancer history, sun protection and level of worry between high-incidence (PEI/NS) and low-incidence (NL) provinces for cutaneous melanoma.&n

Updated on:January 08,2024